Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS. (Q38105267)

28 August 2017

Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS. (English)

1 reference

28 August 2017

1 reference

Shobhit Jain

1

1 reference

28 August 2017

Ninad Desai

series ordinal

2

1 reference

28 August 2017

Amrit Bhangoo

series ordinal

3

1 reference

28 August 2017

1 June 2013

1 reference

Reviews in Endocrine and Metabolic Disorders

28 August 2017

1 reference

28 August 2017

14

1 reference

28 August 2017

2

1 reference

28 August 2017

113-118

1 reference

https://scigraph.springernature.com/pub.10.1007/s11154-013-9245-9

28 August 2017

0 references

cites work

HIV lipodystrophy: prevalence, severity and correlates of risk in Australia

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Lipodystrophy in pediatric HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Increased cardiovascular disease risk indices in HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Evidence for a direct pituitary inhibition by free fatty acids of in vivo growth hormone responses to growth hormone-releasing hormone in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

cis-FFA do not alter membrane depolarization but block Ca2+ influx and GH secretion in KCl-stimulated somatotroph cells. Suggestion for a direct cis-FFA perturbation of the Ca2+ channel opening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Switching effective antiretroviral therapy: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9245-9

Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting

21 January 2018

1 reference

12 December 2020

Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults.

1 reference

12 December 2020

Tripartite control of growth hormone secretion in women during controlled estradiol repletion

1 reference

12 December 2020

Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system

1 reference

12 December 2020

HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: The role of monocyte chemoattractant protein-1

1 reference

12 December 2020

Altered neuroregulation of GH secretion in viscerally obese premenopausal women

1 reference

12 December 2020

Hypopituitarism and HIV-infection: a new comorbidity in the HAART era?

1 reference

12 December 2020

10.1007/S11154-013-9245-9

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference